• **Atezolizumab (TECENTRIQ) + carboplatin/etoposide is a Category 1 preferred immunotherapy/chemotherapy option for first-line treatment of patients with ES-SCLC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)**†‡

*Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

†NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. See the NCCN Guidelines for detailed recommendations.

‡Preferred interventions are based on efficacy, safety, and evidence.

Abbreviations: ES-SCLC, extensive-stage small cell lung cancer; NCCN, National Comprehensive Cancer Network.

---

**Indication**

TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

**Important Safety Information**

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-mediated serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-mediated adverse reactions. Other warnings and precautions include infections, infusion-related reactions, and embryo-fetal toxicity.

Please see accompanying full Prescribing Information and additional Important Safety Information throughout this resource.
**Patient Assistance Information**
Genentech Access Solutions offers a range of access and reimbursement support for your patients and practice:

- Benefits investigations (BIs) and benefits reverification support
- Prior authorization (PA) resources
- Information about authorized specialty pharmacies (SPs) and specialty distributors
- Sample billing and coding information
- Resources for denials and appeals
- Patient assistance options

**Codes for Your Reference**

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TECENTRIQ NDC&lt;sup&gt;2&lt;/sup&gt;</td>
<td>50242-917-01 (on packaging) 50242-0917-01 (used for billing)</td>
<td>1200 mg/20 mL single-dose vial</td>
</tr>
<tr>
<td>TECENTRIQ HCPCS&lt;sup&gt;3&lt;/sup&gt;</td>
<td>J9022</td>
<td>Injection, atezolizumab, 10 mg</td>
</tr>
<tr>
<td>ICD-10-CM&lt;sup&gt;4&lt;/sup&gt;</td>
<td>C33</td>
<td>Malignant neoplasm of trachea</td>
</tr>
<tr>
<td></td>
<td>C34.00–C34.02</td>
<td>Malignant neoplasm of bronchus and lung: main bronchus</td>
</tr>
<tr>
<td></td>
<td>C34.10–C34.12</td>
<td>Malignant neoplasm of bronchus and lung: upper lobe</td>
</tr>
<tr>
<td></td>
<td>C34.2</td>
<td>Malignant neoplasm of bronchus and lung: middle lobe</td>
</tr>
<tr>
<td></td>
<td>C34.30–C34.32</td>
<td>Malignant neoplasm of bronchus and lung: lower lobe</td>
</tr>
<tr>
<td></td>
<td>C34.80–C34.82</td>
<td>Malignant neoplasm of bronchus and lung: overlapping sites</td>
</tr>
<tr>
<td></td>
<td>C34.90–C34.92</td>
<td>Malignant neoplasm of bronchus and lung: unspecified part</td>
</tr>
<tr>
<td>CPT&lt;sup&gt;5&lt;/sup&gt;</td>
<td>96413</td>
<td>Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug</td>
</tr>
<tr>
<td></td>
<td>96415</td>
<td>Chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td></td>
<td>96417</td>
<td>Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (list separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

The table above is provided for informational purposes only. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

**Important Safety Information (cont’d)**

**Serious Adverse Reactions**
Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

**Immune-Mediated Pneumonitis**
- Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis

**Immune-Mediated Hepatitis**
- Immune-mediated hepatitis and liver test abnormalities, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for AST or ALT elevations more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal

Please see accompanying full Prescribing Information and additional Important Safety Information throughout this resource.
Important Safety Information (cont’d)

Immune-Mediated Colitis
• Immune-mediated diarrhea or colitis have occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis

Immune-Mediated Endocrinopathies
• Thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, including diabetic ketoacidosis, and hypophysitis/hypopituitarism have occurred

Other Immune-Mediated Adverse Reactions
• TECENTRIQ can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system. Permanently discontinue TECENTRIQ for Grade 4 immune-mediated adverse reactions involving a major organ

Infections
• Severe infections, including fatal cases, have occurred

Infusion-Related Reactions
• Severe or life-threatening infusion-related reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion-related reactions

Embryo-Fetal Toxicity
• TECENTRIQ can cause fetal harm in pregnant women. Verify pregnancy status prior to initiating TECENTRIQ. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
• Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions
The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ in combination with other antineoplastic drugs for NSCLC and SCLC were fatigue/asthenia (49%), nausea (38%), alopecia (35%), constipation (29%), diarrhea (28%), and decreased appetite (27%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.

Distribution and Fulfillment Information
• TECENTRIQ is available through authorized specialty distributors and wholesalers
• A list of authorized distributors is available at www.genentech-access.com/TECENTRIQ

If you have any distribution-related questions, please contact your representative or call the Genentech Customer Service Department at 1-800-551-2231, Monday through Friday, 6:00 AM to 5:00 PM Pacific Time.

For more information, please contact your BioOncology Field Reimbursement Manager or Genentech BioOncology® Access Solutions for TECENTRIQ by calling 1-866-422-2377 or by visiting https://www.genentech-access.com/TECENTRIQ. To learn more about TECENTRIQ, please visit www.TECENTRIQ.com.

Please see accompanying full Prescribing Information and additional Important Safety Information throughout this resource.


All registered trademarks are the property of their respective owners.